• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar

Galen Institute

  • Home
  • About Us
    • Mission and History
    • Grace-Marie Turner bio
    • Who was Galen?
    • Donate to Galen
  • Activities
    • Core Activities
    • Commentary and Oped Tutorial
    • Our Book
    • Galen Guides
  • Contact Us
  • Major Papers
  • Broadcast Interviews
  • Health Policy Consensus Group

Response to New York Times Article on Medicare Drug Spending

POSTED BY Galen Institute on February 2, 2006.

Dear Editor:

 

Your Feb. 2 article, "Medicare Drug Spending Expected to Be Well Below Estimates," was a powerful rebuttal to critics who claim Part D's market-based approach is failing. As you note, "the intense competition among private insurers" has resulted in lower prices for both medicines and premiums.

 

The drug benefit certainly stumbled out of the gates, and critics charged it showed a failure of the innovative market-based approach to delivering the benefit. In fact, most of the launch-phase problems can be traced to government computers. In particular, when low-income seniors were switched from Medicaid to Medicare to get their drug coverage, federal and state computer programs weren't compatible and names were dropped. And many seniors didn't get enrollment letters because state address lists were out of date.

 

There's plenty of blame to go around, including understaffing of help lines by private insurers. But the real snafu was on the government side.

 

Sincerely,

 

Grace-Marie Turner

President

Galen Institute

Original story at www.nytimes.com

 

Filed Under: Uncategorized

Response to New York Times Article on Medicare Drug Spending

POSTED BY Galen Institute on February 2, 2006.

Dear Editor:

 

Your Feb. 2 article, "Medicare Drug Spending Expected to Be Well Below Estimates," was a powerful rebuttal to critics who claim Part D's market-based approach is failing. As you note, "the intense competition among private insurers" has resulted in lower prices for both medicines and premiums.

 

The drug benefit certainly stumbled out of the gates, and critics charged it showed a failure of the innovative market-based approach to delivering the benefit. In fact, most of the launch-phase problems can be traced to government computers. In particular, when low-income seniors were switched from Medicaid to Medicare to get their drug coverage, federal and state computer programs weren't compatible and names were dropped. And many seniors didn't get enrollment letters because state address lists were out of date.

 

There's plenty of blame to go around, including understaffing of help lines by private insurers. But the real snafu was on the government side.

 

Sincerely,

 

Grace-Marie Turner

President

Galen Institute

Original story at www.nytimes.com

 

Filed Under: Uncategorized

Primary Sidebar

SEARCH

NEW

An American Renaissance in the Care of Health

Our Annual Report

New Paths to Progress

The Laffer Curve

Subscribe to our Newsletter

* = required field
unsubscribe from list
(After subscribing, you will receive a confirmation email which is frequently found in the junk mail folder.)

Recent Newsletters

Categories

Social Media

Like Us On Facebook

Twitter:
@gracemarietweet
@galeninstitute

Copyright Galen Institute at Donors. © 2025; · Log in